177 related articles for article (PubMed ID: 29683208)
1. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras.
Mallangada NA; Vargas JM; Thomas S; DiGiovanni MG; Vaeth BM; Nemesure MD; Wang R; LaComb JF; Williams JL; Golub LM; Johnson F; Mackenzie GG
Mol Carcinog; 2018 Sep; 57(9):1130-1143. PubMed ID: 29683208
[TBL] [Abstract][Full Text] [Related]
2. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.
Mackenzie GG; Bartels LE; Xie G; Papayannis I; Alston N; Vrankova K; Ouyang N; Rigas B
Neoplasia; 2013 Oct; 15(10):1184-95. PubMed ID: 24204197
[TBL] [Abstract][Full Text] [Related]
3. Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways.
Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Shankar S; Srivastava RK
PLoS One; 2014; 9(4):e92161. PubMed ID: 24694877
[TBL] [Abstract][Full Text] [Related]
4. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
6. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
7. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
8. Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.
Mattheolabakis G; Wang R; Rigas B; Mackenzie GG
Int J Oncol; 2017 Oct; 51(4):1035-1044. PubMed ID: 28849098
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
Lang SA; Schachtschneider P; Moser C; Mori A; Hackl C; Gaumann A; Batt D; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2008 Nov; 7(11):3509-18. PubMed ID: 19001434
[TBL] [Abstract][Full Text] [Related]
10. Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells.
Hong Z; Wang Z; Zhou B; Wang J; Tong H; Liao Y; Zheng P; Jamshed MB; Zhang Q; Chen H
Int J Oncol; 2020 Mar; 56(3):783-793. PubMed ID: 31922213
[TBL] [Abstract][Full Text] [Related]
11. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S
Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
Zhong H; Sanchez C; Spitzer D; Plambeck-Suess S; Gibbs J; Hawkins WG; Denardo D; Gao F; Pufahl RA; Lockhart AC; Xu M; Linehan D; Weber J; Wang-Gillam A
PLoS One; 2013; 8(10):e77243. PubMed ID: 24130864
[TBL] [Abstract][Full Text] [Related]
13. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
14. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Zhang W; Li H; Yang Y; Liao J; Yang GY
Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer heterogeneity and response to Mek inhibition.
Pedersen K; Bilal F; Bernadó Morales C; Salcedo MT; Macarulla T; Massó-Vallés D; Mohan V; Vivancos A; Carreras MJ; Serres X; Abu-Suboh M; Balsells J; Allende E; Sagi I; Soucek L; Tabernero J; Arribas J
Oncogene; 2017 Oct; 36(40):5639-5647. PubMed ID: 28581516
[TBL] [Abstract][Full Text] [Related]
16. Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway.
Wu SZ; Xu HC; Wu XL; Liu P; Shi YC; Pang P; Deng L; Zhou GX; Chen XY
Phytomedicine; 2019 Jun; 59():152895. PubMed ID: 30913453
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
18. Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.
Luo D; Fraga-Lauhirat M; Millings J; Ho C; Villarreal EM; Fletchinger TC; Bonfiglio JV; Mata L; Nemesure MD; Bartels LE; Wang R; Rigas B; Mackenzie GG
Carcinogenesis; 2019 Dec; 40(12):1480-1491. PubMed ID: 30994173
[TBL] [Abstract][Full Text] [Related]
19. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways.
Li W; Wang Z; Xiao X; Han L; Wu Z; Ma Q; Cao L
Oncol Rep; 2019 Jan; 41(1):650-658. PubMed ID: 30542713
[TBL] [Abstract][Full Text] [Related]
20. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
